ISRCTN56475197 https://doi.org/10.1186/ISRCTN56475197

# A study of computed tomography (CT) scan frequency in patients with stage I testicular teratoma

| | | |
|---|---|---|
| **Submission date**<br>06/04/2000 | **Recruitment status**<br>No longer recruiting | [_] Prospectively registered<br>[_] Protocol<br>[_] Statistical analysis plan<br>[X] Results<br>[_] Individual participant data |
| **Registration date**<br>06/04/2000 | **Overall study status**<br>Completed | |
| **Last Edited**<br>28/10/2021 | **Condition category**<br>Cancer | |

**Plain English summary of protocol**
Not provided at time of registration

## Contact information

**Type(s)**
Scientific

**Contact name**
Miss Sharon Naylor

**Contact details**
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA
-
not@provided.com

## Additional identifiers

**ClinicalTrials.gov (NCT)**
NCT00003420

**Protocol serial number**
TE08

## Study information

### Scientific Title
A study of computed tomography (CT) scan frequency in patients with stage I testicular teratoma

### Study objectives
To assess the value of frequent abdominal and chest CT scans in the follow-up of patients with stage I non-seminomatous germ cell tumours (NSGCT) who are on a surveillance programme. After baseline scans confirming stage I disease, patients will be randomised between two and five further CT scans during their follow up, with the nature and frequency of all other investigations remaining constant.

### Ethics approval required
Old ethics approval format

### Ethics approval(s)
Not provided at time of registration.

### Primary study design
Interventional

### Study design
Randomised controlled trial

### Study type(s)
Not Specified

### Health condition(s) or problem(s) studied
Cancer

### Interventions
1. One group receives two CT scans
2. The other group receives five CT scans

### Intervention Type
Other

### Phase
Not Specified

### Primary outcome(s)
Stage of the disease at relapse (IGCC Classification), time from entry to detection of relapse.

### Key secondary outcome(s)
Overall survival, identification of the first investigation or sign prompting diagnosis of relapse, incidence of second malignancies and balance of costs of treatment determined through health economics study

### Completion date
30/04/2003

## Eligibility

### Key inclusion criteria
1. Histologically confirmed stage I non-seminomatous germ cell tumour of the testis
2. Patients must be able to attend for regular surveillance
3. The interval between orchidectomy and randomisation should not exceed 8 weeks
4. No co-existent or previously treated malignant disease, except successfully treated non-melanotic skin cancer

### Participant type(s)
Patient

### Healthy volunteers allowed
No

### Age group
Not Specified

### Sex
Male

### Key exclusion criteria
Not provided at time of registration

### Date of first enrolment
01/12/1997

### Date of final enrolment
30/04/2003

## Locations

### Countries of recruitment
United Kingdom

England

### Study participating centre
**MRC Clinical Trials Unit**
London
United Kingdom
NW1 2DA

## Sponsor information

### Organisation

Medical Research Council (MRC) (UK)

# Funder(s)

### Funder type
Research council

### Funder Name
Medical Research Council (UK)

### Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

### Funding Body Type
Government organisation

### Funding Body Subtype
National government

### Location
United Kingdom

# Results and Publications

### Individual participant data (IPD) sharing plan
Not provided at time of registration

### IPD sharing plan summary
Not provided at time of registration

### Study outputs

| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results | 10/04/2007 | | Yes | No |
| Plain English results | | | 28/10/2021 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |